Cargando…
The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
BACKGROUND: Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033704/ https://www.ncbi.nlm.nih.gov/pubmed/33836694 http://dx.doi.org/10.1186/s12885-021-08129-4 |
_version_ | 1783676450330640384 |
---|---|
author | Amin, Saber Baine, Michael Meza, Jane Lin, Chi |
author_facet | Amin, Saber Baine, Michael Meza, Jane Lin, Chi |
author_sort | Amin, Saber |
collection | PubMed |
description | BACKGROUND: Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site. METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Cox proportional hazard model adjusted for age at diagnosis, race, sex, place of living, income, education, primary tumor type, year of diagnosis, chemotherapy, radiation therapy (RT), and surgery of the primary cancer site was used to determine treatment facility-associated hazard ratios (HR) for survival. Overall survival was the primary outcome, which was analyzed with multivariable Cox proportional hazards regression modeling. RESULTS: A total of 93,633 patients were analyzed, among whom 31,579/93,633 (34.09%) were treated at academic centers. Based on the log-rank analysis, patients who received treatment at an academic facility had significantly improved OS (median OS: 6.18, CI: 6.05–6.31 vs. 4.57, CI: 4.50–4.63 months; p < 0.001) compared to patients who were treated at non-academic facilities. In the multivariable Cox regression analysis, receiving treatment at an academic facility was associated with significantly improved OS (HR: 0.85, CI: 0.84–0.87; p < 0.001) compared to non-academic facility. CONCLUSIONS: In this extensive analysis of the NCDB, receiving treatment at academic centers was associated with significantly improved OS compared to treatment at non-academic centers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08129-4. |
format | Online Article Text |
id | pubmed-8033704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80337042021-04-09 The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type Amin, Saber Baine, Michael Meza, Jane Lin, Chi BMC Cancer Research Article BACKGROUND: Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site. METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Cox proportional hazard model adjusted for age at diagnosis, race, sex, place of living, income, education, primary tumor type, year of diagnosis, chemotherapy, radiation therapy (RT), and surgery of the primary cancer site was used to determine treatment facility-associated hazard ratios (HR) for survival. Overall survival was the primary outcome, which was analyzed with multivariable Cox proportional hazards regression modeling. RESULTS: A total of 93,633 patients were analyzed, among whom 31,579/93,633 (34.09%) were treated at academic centers. Based on the log-rank analysis, patients who received treatment at an academic facility had significantly improved OS (median OS: 6.18, CI: 6.05–6.31 vs. 4.57, CI: 4.50–4.63 months; p < 0.001) compared to patients who were treated at non-academic facilities. In the multivariable Cox regression analysis, receiving treatment at an academic facility was associated with significantly improved OS (HR: 0.85, CI: 0.84–0.87; p < 0.001) compared to non-academic facility. CONCLUSIONS: In this extensive analysis of the NCDB, receiving treatment at academic centers was associated with significantly improved OS compared to treatment at non-academic centers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08129-4. BioMed Central 2021-04-09 /pmc/articles/PMC8033704/ /pubmed/33836694 http://dx.doi.org/10.1186/s12885-021-08129-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Amin, Saber Baine, Michael Meza, Jane Lin, Chi The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
title | The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
title_full | The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
title_fullStr | The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
title_full_unstemmed | The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
title_short | The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
title_sort | impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033704/ https://www.ncbi.nlm.nih.gov/pubmed/33836694 http://dx.doi.org/10.1186/s12885-021-08129-4 |
work_keys_str_mv | AT aminsaber theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT bainemichael theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT mezajane theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT linchi theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT aminsaber impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT bainemichael impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT mezajane impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype AT linchi impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype |